Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
Cardiovascular metabolic comorbidities made patients more susceptible to the 2019 novel coronavirus ( 2019-nCoV) disease. A meta-analysis of eligible studies summarizes the prevalence of cardiovascular metabolic diseases in COVID-19. At least 8.0% of patients with COVID-19 suffered an acute cardiac injury. Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition. On the other hand, COVID-19 can, in turn, aggravate the damage to the
